Dichloroacetate (DCA) for Cancer

The Bottom Line

Dichloroacetate (DCA) is a small molecule that inhibits pyruvate dehydrogenase kinase (PDK), forcing cancer cells to switch from their abnormal glycolytic metabolism back to normal oxidative phosphorylation. This reversal of the Warburg effect makes cancer cells vulnerable to apoptosis. The mechanism is scientifically compelling and the drug is dirt cheap (~$15/month). However, Phase I trials showed stabilization rather than regression, and peripheral neuropathy is a significant dose-limiting side effect. DCA remains investigational — it has generated enormous interest but has not yet demonstrated definitive clinical benefit in cancer patients.

What It Is

Dichloroacetate is a structural analog of acetic acid. It was previously used clinically for lactic acidosis in children with congenital mitochondrial disorders. It is not FDA-approved for cancer treatment. DCA is notable in the repurposing community because it is one of the cheapest possible anticancer approaches (about $15/month for research-grade powder) and has a plausible mechanism that attacks cancer metabolism directly.

How It Works Against Cancer

• PDK inhibition: DCA's primary mechanism is inhibiting pyruvate dehydrogenase kinase (PDK). PDK normally phosphorylates and disables pyruvate dehydrogenase (PDH), the enzyme that gates pyruvate into the mitochondria. By inhibiting PDK, DCA reactivates PDH, funneling pyruvate into oxidative phosphorylation instead of glycolysis.
• Warburg effect reversal: Cancer cells rely on glycolysis even in the presence of oxygen (the Warburg effect). This provides them with metabolic intermediates for rapid growth but also makes them dependent on avoiding mitochondrial apoptosis. Forcing them back toward oxidative phosphorylation disrupts this adaptation.
• Mitochondrial membrane depolarization: When cancer cells are forced to use mitochondria, their damaged or adapted mitochondria cannot handle the metabolic stress — cytochrome c is released, triggering apoptosis.
• Lactate reduction: By redirecting pyruvate away from lactate production, DCA reduces the acidic tumor microenvironment that promotes invasion and suppresses immune surveillance.
• Selective effect: Normal cells already primarily use oxidative phosphorylation and are minimally affected by DCA. Cancer cells, dependent on glycolysis, are disproportionately impacted.

The Science: Key Studies

The Landmark Paper — Bonnet et al., Cancer Cell 2007

This paper launched the DCA in cancer movement. The researchers showed that DCA induced apoptosis in GBM, breast, and lung cancer cells in vitro and suppressed tumor growth in rat xenografts. Critically, DCA concentrations that killed cancer cells had minimal effects on normal neurons — suggesting a therapeutic window. The paper was widely covered in the popular press and generated enormous patient interest, though it was subsequently criticized for overstating the findings.

Phase I Clinical Trial — Michelakis et al., 2014

The first human trial of DCA in cancer patients. 15 adults with recurrent malignant brain tumors received oral DCA. The study established that DCA was well-tolerated at metabolic doses (10mg/kg/day). All 8 evaluable patients showed disease stabilization through the first 4 weeks of treatment. The dose-limiting toxicity was peripheral neuropathy — a known side effect of DCA from its use in lactic acidosis. This trial established feasibility but not efficacy.

More Recent Evidence

A 2024 comprehensive review in PMC11206832 acknowledged DCA's compelling mechanism but noted "some facts and many doubts" — pointing to inconsistent results across studies and concerns about whether the concentrations needed for effect can be safely achieved in humans. A glioblastoma trial (NCT05120284) was registered but results appear pending. The compound continues to be studied in combination approaches.

Evidence Grade: C — Early / Limited

Despite enormous interest and strong mechanistic rationale, DCA lacks completed Phase II or III trials demonstrating clinical benefit in cancer. The best evidence is the Phase I stabilization signal in brain tumors, which is encouraging but far from definitive. The drug's major liability is peripheral neuropathy, which limits how aggressively it can be dosed. Whether the doses needed for anticancer effect are achievable without unacceptable neuropathy remains an open question.

Protocol Considerations

• Starting dose: 10-12.5 mg/kg/day orally, divided into 2 doses
• Low neuropathy protocol: Some practitioners start lower (6.25 mg/kg/day) to minimize neuropathy risk
• Monitoring: Regular neurological exams recommended; stop at first signs of neuropathy
• Quality matters: Research-grade DCA powder from reputable suppliers is recommended; quality control of available products varies
• Combination approaches: Some protocols combine DCA with metformin (dual glycolysis targeting) or with standard chemotherapy

Risks and Limitations

• Peripheral neuropathy: The main dose-limiting toxicity. Can be severe and is often irreversible. Affects hands and feet. Requires monitoring and dose adjustment.
• Not FDA-approved for cancer: No regulatory approval means variable product quality
• Genetic variability: GSTZ1 gene polymorphisms affect DCA metabolism — some patients are slow metabolizers
• Hepatotoxicity: Liver function should be monitored
• Encephalopathy: Rare reversible encephalopathy reported at higher doses
• Drug interactions: May interact with pyruvate dehydrogenase-related medications

Our Assessment

DCA has one of the most elegant mechanistic stories in cancer repurposing — attacking cancer metabolism by reversing the Warburg effect. The Phase I trial was encouraging enough to justify further study, but the field has not progressed to Phase II/III in the nearly 20 years since the original paper. The neuropathy problem is real and may cap the achievable dose below the effective range. At ~$15/month, it is one of the most affordable options on this list, which explains its continued popularity despite limited clinical evidence. Worth discussing with an oncologist as an adjunct, particularly for brain tumor patients already familiar with metabolic approaches, but not a replacement for standard care.

Sources

• Bonnet et al. Cancer Cell 2007;11(1):37-51 — The landmark DCA/Warburg paper
• PMC4455946 — Phase I brain tumor trial
• PMC11206832 — "Some Facts and Many Doubts" (2024 comprehensive review)
• Nature BJC 2008 — "DCA as potential metabolic-targeting therapy"
• ClinicalTrials.gov NCT05120284 — DCA in glioblastoma trial
• PMC9937275 — DCA pharmacology and clinical considerations